YUSIMRY 40 mg/.8mL
adalimumab-aqvh · INJECTION, SOLUTION · Meitheal Pharmaceuticals Inc.
YUSIMRY is a injection, solution containing adalimumab-aqvh at 40 mg/.8mL, taken subcutaneous. Manufactured by Meitheal Pharmaceuticals Inc..
Key Facts
- Brand Name
- YUSIMRY
- Generic Name
- adalimumab-aqvh
- NDC Code (Product)
71288-815- Manufacturer
- Meitheal Pharmaceuticals Inc.
- Strength
- 40 mg/.8mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761216
- Drug Class
- Tumor Necrosis Factor Blocker [EPC]
- Marketing Start
- 07/01/2023
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is YUSIMRY used for?
YUSIMRY contains adalimumab-aqvh. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is YUSIMRY a controlled substance?
YUSIMRY is not classified as a controlled substance by the DEA.
What is the generic name for YUSIMRY?
The generic name for YUSIMRY is adalimumab-aqvh. There are no other listed brand versions of adalimumab-aqvh.
What is the NDC code for YUSIMRY 40 mg/.8mL?
The NDC (National Drug Code) for YUSIMRY 40 mg/.8mL is 71288-815, listed by Meitheal Pharmaceuticals Inc..
Other YUSIMRY Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)